Biogen Inc. (FRA:IDP)
117.05
0.00 (0.00%)
Last updated: Sep 30, 2025, 9:06 AM CET
Biogen Employees
Biogen had 7,605 employees as of December 31, 2024. The number of employees increased by 35 or 0.46% compared to the previous year.
Employees
7,605
Change (1Y)
35
Growth (1Y)
0.46%
Revenue / Employee
€1,119,322
Profits / Employee
€171,364
Market Cap
17.50B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 7,605 | 35 | 0.46% |
Dec 31, 2023 | 7,570 | -1,155 | -13.24% |
Dec 31, 2022 | 8,725 | -885 | -9.21% |
Dec 31, 2021 | 9,610 | 510 | 5.60% |
Dec 31, 2020 | 9,100 | 1,700 | 22.97% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
SAP SE | 109,121 |
Siemens Aktiengesellschaft | 327,000 |
Deutsche Telekom AG | 198,194 |
Allianz SE | 156,626 |
Rheinmetall AG | 28,539 |
Siemens Energy AG | 98,000 |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 44,224 |
Deutsche Bank Aktiengesellschaft | 89,753 |
Biogen News
- 2 days ago - “LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China - GlobeNewsWire
- 6 days ago - Biogen Inc. (BIIB) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 6 days ago - LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia - GlobeNewsWire
- 7 days ago - US FDA declines to approve higher-dose of Biogen's genetic disorder drug - Reuters
- 7 days ago - Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen - GlobeNewsWire
- 12 days ago - A Look Into Biogen Inc's Price Over Earnings - Benzinga
- 12 days ago - Biogen (BIIB) to Acquire Alcyone Therapeutics for $85M - GuruFocus
- 12 days ago - December 19th Options Now Available For Biogen (BIIB) - Nasdaq